Abstract 1902
Background
mFOLFIRINOX and GEM are standard chemotherapy for pts with PDAC. This single-arm phase 2 trial assessed the efficacy and safety of perioperative chemotherapy consisted of preoperative mFOLFIRINOX and postoperative GEM in pts with BR/LA-PDAC.
Methods
Pts with histologically proven and radiologically confirmed BR/LA-PDAC as defined by NCCN criteria were eligible. Pts received 8 cycles of preoperative mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, 5-FU 2,400 mg/m2 over 46 hours, and leucovorin 400 mg/m2), every 2 weeks. For pts who underwent surgery, postoperative GEM (1,000 mg/m2 D1, 8, 15, every 4 weeks) was given for 6 cycles. Primary endpoint was 1-year progression-free survival (PFS) rate and secondary endpoints were PFS, overall survival (OS) and curative surgery rate. A total of 44 pts were required to show the improvement in 1-year PFS rates from 30% to 50% with a two-sided alpha of 0.05, beta of 0.8 and drop-out rates of 10%.
Results
Between May/2016 and Mar/2018, 44 patients were enrolled. Median age was 60 years (range, 35-76) and 26 pts (59%) were male. Pancreas head was most common site (n = 26, 59%), and 29 (66%) and 15 (34%) pts had BR- and LA-PDAC, respectively. With mFOLFIRINOX, response rate was 34% and surgery was done in 27 pts (61%); 22 and 5 pts achieved R0 and R1 resection, respectively, and postoperative GEM was given in 26 patients (96%). With median follow-up of 20.7 months (95% CI, 14.4-27.0), 1-year PFS rate was 52.0% (95% CI, 37.1-66.9), and 2-year OS rate was 49.8% (95% CI, 38.2-71.4). Median PFS and OS was 12.2 months (95% CI, 7.9-15.9), and 22.3 months (95% CI, 11.3-33.3), respectively. Median OS was significantly prolonged in pts who underwent surgery compared to those who did not (26.2 months [95% CI, 23.1-29.3] vs 9.0 months [95% CI, 6.6-11.4 months]; p < 0.001). For pts with surgery, R1 resection was significantly associated with poor postoperative OS compared to R0 resection (p = 0.04).
Conclusions
Perioperative chemotherapy using mFOLFIRINOX and GEM was feasible and effective for pts with BR/LA-PDAC.
Clinical trial identification
NCT02749136.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Boryung Pharmaceuticals.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract